These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25747125)

  • 1. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
    Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
    Klimek L; Bousquet J; Price D
    Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
    Meltzer EO; LaForce C; Ratner P; Price D; Ginsberg D; Carr W
    Allergy Asthma Proc; 2012; 33(4):324-32. PubMed ID: 22856633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
    Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J
    Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MP29-02: a breakthrough for the treatment of allergic rhinitis.
    Bernstein JA
    Expert Opin Pharmacother; 2013 Oct; 14(15):2101-13. PubMed ID: 23977840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
    Klimek L; Bachert C; Mösges R; Munzel U; Price D; Virchow JC; Wahn U; Bousquet J
    Allergy Asthma Proc; 2015; 36(1):40-7. PubMed ID: 25562555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
    Derendorf H; Meltzer EO; Hermann R; Canonica GW
    Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
    Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
    Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
    Meltzer E; Ratner P; Bachert C; Carr W; Berger W; Canonica GW; Hadley J; Lieberman P; Hampel FC; Mullol J; Munzel U; Price D; Scadding G; Virchow JC; Wahn U; Murray R; Bousquet J
    Int Arch Allergy Immunol; 2013; 161(4):369-77. PubMed ID: 23652808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
    Berger WE; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S
    J Allergy Clin Immunol Pract; 2014; 2(2):179-85. PubMed ID: 24607046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azelastine and fluticasone nasal spray: any advantage?
    Drug Ther Bull; 2014 Feb; 52(2):21-4. PubMed ID: 24504481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
    Kortekaas Krohn I; Callebaut I; Alpizar YA; Steelant B; Van Gerven L; Skov PS; Kasran A; Talavera K; Wouters MM; Ceuppens JL; Seys SF; Hellings PW
    Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escaping the trap of allergic rhinitis.
    Rossi O; Massaro I; Caminati M; Quecchia C; Fassio F; Heffler E; Canonica GW
    Clin Mol Allergy; 2015; 13(1):17. PubMed ID: 26244040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
    Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J
    J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
    Price D; Shah S; Bhatia S; Bachert C; Berger W; Bousquet J; Carr W; Hellings P; Munzel U; Scadding G; Lieberman P
    J Investig Allergol Clin Immunol; 2013; 23(7):495-503. PubMed ID: 24654314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.
    Bernstein JA
    Curr Med Res Opin; 2007 Oct; 23(10):2441-52. PubMed ID: 17723160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.
    Ilyina NI; Edin AS; Astafieva NG; Lopatin AS; Sidorenko IV; Ukhanova OP; Khanova FM
    Int Arch Allergy Immunol; 2019; 178(3):255-263. PubMed ID: 30677766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark.
    Haahr PA; Jacobsen C; Christensen ME
    Int Forum Allergy Rhinol; 2019 Apr; 9(4):388-395. PubMed ID: 30659752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal spray medications for maintenance therapy of allergic rhinitis.
    Berger WE; Meltzer EO
    Am J Rhinol Allergy; 2015; 29(4):273-82. PubMed ID: 26132312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.